SCN2A-Related Developmental and Epileptic Encephalopathy

Genetic MONDO:0013388 Pathograph 8 Show in embeddings browser Epilepsy Neurological Disease

SCN2A-related developmental and epileptic encephalopathy (DEE11) is caused by pathogenic variants in SCN2A, which encodes the voltage-gated sodium channel Nav1.2. The disorder has a striking mechanistic dichotomy with opposite treatment implications. Gain-of-function variants increase Nav1.2 sodium current and typically produce early-infantile-onset (usually before three months) epilepsy that often responds to sodium-channel-blocking drugs. Loss-of-function variants reduce Nav1.2 current and typically produce later-onset (after three months) epilepsy and/or autism and intellectual disability, in which sodium-channel blockers can paradoxically worsen seizures. Determining the functional consequence of the variant is therefore central to management.

Ask OpenScientist

Ask a research question about SCN2A-Related Developmental and Epileptic Encephalopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Mappings
1
Inheritance
5
Pathophys.
10
Phenotypes
2
Hypotheses
3
Gaps
8
Pathograph
1
Genes
3
Medical Actions
1
Trials
1
Deep Research
🏷

Classifications

Harrison's Part
NEUROLOGIC GENETICS ENVIRONMENT DISEASE
Channelopathy
neurological channelopathy
🔗

Mappings

MONDO
MONDO:0013388 developmental and epileptic encephalopathy, 11
skos:exactMatch MONDO
MONDO:0013388 is the SCN2A developmental and epileptic encephalopathy (DEE11) concept.
👪

Inheritance

1
Autosomal dominant (de novo) HP:0000006
SCN2A-DEE is autosomal dominant; the great majority of variants are de novo. Recurrence risk to siblings is low but not zero (on the order of 1-2%) because of the possibility of parental germline (or low-level somatic) mosaicism.
Autosomal dominant inheritance
Show evidence (3 references)
PMID:34859793 SUPPORT Human Clinical
"With regards to inheritance pattern, de novo heterozygous mutations accounted for the majority (104/118; 88.1%)"
In a genetically diagnosed early-infantile-onset DEE cohort (which included SCN2A cases), de novo heterozygous variants accounted for the large majority, supporting the de novo autosomal dominant mode of inheritance.
PMID:31077350 SUPPORT Human Clinical
"Parental mosaicism was observed in the following genes: SCN1A, SCN2A, SCN8A, and STXBP1."
Documents parental somatic mosaicism for SCN2A variants that appeared de novo, the basis for the small but non-zero sibling recurrence risk.
PMID:31077350 SUPPORT Human Clinical
"parents affected by low-grade mosaicism are faced with an increased recurrence risk for transmitting the pathogenic variant, compared to the overall recurrence risk for a second affected child estimated at approximately 1%"
Quantifies the baseline sibling recurrence risk (~1%) and the mosaicism mechanism that raises it in individual families.
◈

Mechanistic Hypotheses

2
Gain-of-Function / Early-Onset Model
scn2a_gain_of_function_early_onset CANONICAL
Evidence balance 2 support
Gain-of-function SCN2A variants increase Nav1.2 sodium current and neuronal excitability, producing early-infantile-onset epilepsy (typically before three months of age) that often responds to sodium-channel-blocking drugs.
Pathograph links
SCN2A Variant (Nav1.2 Dysfunction) -> Increased Nav1.2 Sodium Current (Gain of Function) DIRECT Gain-of-function variants increase Nav1.2 sodium current.
Increased Nav1.2 Sodium Current (Gain of Function) -> Neuronal Hyperexcitability and Network Dysfunction DIRECT Increased sodium current directly raises neuronal excitability.
Show evidence (2 references)
PMID:31904126 SUPPORT Human Clinical
"Some missense, gain of function variants tend to present in early infancy with epilepsy"
States the gain-of-function / early-infantile-onset arm of the SCN2A dichotomy that this hypothesis group models.
PMID:28256214 SUPPORT In Vitro
"Variants observed in infantile seizures are predominantly missense, leading to a gain of function and increased neuronal excitability."
Voltage-clamp characterization links infantile-seizure SCN2A variants to gain of Nav1.2 function and increased neuronal excitability.
Loss-of-Function / Later-Onset Model
scn2a_loss_of_function_later_onset CANONICAL
Evidence balance 3 support
Loss-of-function SCN2A variants reduce Nav1.2 current, impairing action potential firing in excitatory neurons, and typically produce later-onset (after three months) epilepsy and/or autism and intellectual disability, in which sodium-channel blockers can worsen seizures.
Pathograph links
SCN2A Variant (Nav1.2 Dysfunction) -> Decreased Nav1.2 Sodium Current (Loss of Function) DIRECT Loss-of-function variants reduce Nav1.2 sodium current.
Decreased Nav1.2 Sodium Current (Loss of Function) -> Neuronal Hyperexcitability and Network Dysfunction INDIRECT KNOWN INTERMEDIATES Reduced excitatory-neuron firing dysregulates developing circuits and network excitability.
Show evidence (3 references)
PMID:37578743 SUPPORT In Vitro
"predominantly gain-of-function variants cause neonatal-onset epilepsy, whereas loss-of-function variants are associated with ASD and ID"
States the loss-of-function arm (autism and intellectual disability) of the SCN2A functional dichotomy modeled by this hypothesis group.
PMID:28256214 SUPPORT In Vitro
"In contrast to gain of function variants that contribute to seizure, we found that all ASD-associated variants dampened or eliminated channel function."
Direct electrophysiological demonstration that autism-associated SCN2A variants reduce or abolish Nav1.2 function.
PMID:37578743 SUPPORT In Vitro
"Many epilepsy-associated variants in our study exhibited complex patterns of gain- and loss-of-functions that are difficult to classify by a simple binary scheme."
Important caveat: high-throughput automated patch-clamp shows many variants have mixed gain/loss features, so the two-arm model is a useful simplification rather than a strict binary.
?

Discussions and Knowledge Gaps

3
Because sodium-channel blockers help gain-of-function SCN2A epilepsy but can worsen loss-of-function forms, treatment hinges on knowing the functional consequence of a variant. How reliably can gain versus loss of function be inferred at the bedside from age at onset (before versus after three months) and variant type, and how quickly can functional assays resolve ambiguous (e.g., missense, VUS) variants to guide drug choice?
KNOWLEDGE GAP OPEN scn2a-functional-classification-for-treatment
Attached to
pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function) pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)
Onset age and truncating status are useful proxies but not perfect, and many missense variants are of uncertain effect; a wrong inference can select a drug that worsens seizures. A fast, validated functional-classification pathway would directly change management.
Proposed experiments
Rapid functional-classification pipeline
scn2a-functional-assay-pipeline
Benchmark high-throughput electrophysiology and predictive models against clinical response to sodium-channel blockers across a large SCN2A variant set to establish a rapid gain/loss classification that guides therapy.
Readouts
Predicted gain/loss versus clinical drug response
pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)
Decision criterion
A classifier that predicts drug response better than onset age alone would support its clinical use.
Would support
pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function) pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)
Show evidence (1 reference)
PMID:28379373 SUPPORT Human Clinical
"sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening"
Demonstrates the opposite treatment response by arm, motivating rapid functional classification.
Antisense-oligonucleotide and other gene-directed strategies that lower or raise Nav1.2 are in development for SCN2A disorders. Can allele- or direction-specific approaches safely correct the gain-of-function arm (lowering Nav1.2) and the loss-of-function arm (raising Nav1.2) without tipping the opposite way, and in what developmental window must they act?
KNOWLEDGE GAP OPEN scn2a-precision-therapy-aso
Attached to
pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)
Because the two arms need opposite corrections, a one-size intervention is unsafe; the therapeutic window and the reversibility of the encephalopathy once established are open questions central to precision therapy.
Proposed experiments
Direction-specific Nav1.2 modulation study
scn2a-directional-therapy-model
Test gain-lowering (e.g., ASO knockdown) and loss-restoring approaches in genotype-matched SCN2A models across developmental stages, measuring seizure, network, and behavioral outcomes and off-target excitability.
Readouts
Outcome of directional Nav1.2 modulation by arm and timing
pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)
Would support
pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)
Show evidence (2 references)
PMID:34850743 SUPPORT Model Organism
"Across a range of behavioral tests, Scn2a ASO-treated Q/+ mice were largely indistinguishable from WT mice, suggesting treatment is well tolerated."
Shows that direction-specific Nav1.2 lowering was tolerated in a gain-of-function model, the starting point for the open question of whether such approaches are safe without tipping toward the opposite arm.
PMID:29691040 SUPPORT Human Clinical
"raises the possibility that ligands that selectively enhance or diminish channel function may improve symptoms"
Frames the direction-specific therapeutic strategy (enhancing versus diminishing Nav1.2) that this knowledge gap interrogates.
Loss-of-function SCN2A variants produce autism and intellectual disability, sometimes with little or no epilepsy. How does reduced Nav1.2 current in developing excitatory neurons translate into autism and cognitive impairment independent of seizures, and does this reflect impaired dendritic excitability and synaptic maturation?
KNOWLEDGE GAP OPEN scn2a-lof-autism-mechanism
Attached to
pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)
The seizure-independent neurodevelopmental phenotype of Nav1.2 loss of function is mechanistically distinct from the epileptogenic arm and is only partially understood, yet it defines the prognosis and therapeutic targets for a large share of SCN2A patients.
Proposed experiments
Nav1.2 loss-of-function neurodevelopmental study
scn2a-lof-neurodevelopment
Use human neurons and animal models with SCN2A loss-of-function variants to link reduced Nav1.2 current to dendritic excitability, synaptic maturation, and behavioral phenotypes independent of overt seizures.
Readouts
Dendritic/synaptic phenotype and behavior with Nav1.2 loss
pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)
Would support
pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)
Show evidence (2 references)
PMID:31230762 SUPPORT Model Organism
"The link between an axonal sodium channel and ASD, a disorder typically attributed to synaptic or transcriptional dysfunction, is unclear."
States the open question this knowledge gap captures: how an axonal sodium channel defect produces autism.
PMID:31230762 SUPPORT Model Organism
"These results reveal a novel dendritic function for NaV1.2, providing insight into cellular mechanisms probably underlying circuit and behavioral dysfunction in ASD."
Supports the proposed dendritic-excitability/synaptic-maturation explanation named in the prompt, while the authors' hedged wording shows it remains a partial answer.
⚙

Pathophysiology

5
SCN2A Variant (Nav1.2 Dysfunction)
A pathogenic variant in SCN2A alters the function of the voltage-gated sodium channel Nav1.2. This node captures the single concept of the initiating channel lesion, whose functional direction (gain versus loss of function) sets the clinical arm.
Gain-of-Function / Early-Onset Model Loss-of-Function / Later-Onset Model
SCN2A hgnc:10588 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves SCN2A (hgnc:10588). hgnc:10588 is a gene from the HUGO Gene Nomenclature Committee.
voltage-gated sodium channel activity GO:0005248 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves voltage-gated sodium channel activity (GO:0005248). GO:0005248 is a molecular function from the Gene Ontology.
Downstream
Increased Nav1.2 Sodium Current (Gain of Function) Gain-of-function variants increase Nav1.2 sodium current. Gain-of-Function / Early-Onset Model
Decreased Nav1.2 Sodium Current (Loss of Function) Loss-of-function variants reduce Nav1.2 sodium current. Loss-of-Function / Later-Onset Model
Show evidence (2 references)
PMID:29691040 SUPPORT Human Clinical
"Advances in gene discovery for neurodevelopmental disorders have identified SCN2A dysfunction as a leading cause of infantile seizures, autism spectrum disorder, and intellectual disability. SCN2A encodes the neuronal sodium channel NaV1.2."
Establishes the initiating lesion of this entry: SCN2A variants disrupting the neuronal sodium channel Nav1.2 as a leading cause of infantile seizures and neurodevelopmental disease.
PMID:29691040 SUPPORT In Vitro
"Functional assays demonstrate strong correlation between genotype and phenotype."
Supports the modeling choice that the functional direction of the variant (gain versus loss of function) is what sets the clinical arm. The genotype-phenotype correlation is established by in vitro functional (electrophysiological) characterization of the variants.
Increased Nav1.2 Sodium Current (Gain of Function)
Gain-of-function variants increase the Nav1.2 sodium current (through enhanced activation, impaired inactivation, or increased persistent current), directly raising neuronal excitability. This node captures the single concept of the gain-of-function channel state and conforms to the shared epilepsy final common pathway.
Gain-of-Function / Early-Onset Model
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Sodium ion transmembrane transport GO:0035725 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased Sodium ion transmembrane transport (GO:0035725). GO:0035725 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
Neuronal Hyperexcitability and Network Dysfunction Increased sodium current directly raises neuronal excitability. Gain-of-Function / Early-Onset Model
Show evidence (1 reference)
PMID:28379373 SUPPORT In Vitro
"mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function"
Functional studies show early-infantile-epilepsy SCN2A mutations increase sodium channel activity (gain of function).
Decreased Nav1.2 Sodium Current (Loss of Function)
Loss-of-function variants reduce the Nav1.2 sodium current, impairing action potential initiation and propagation especially in excitatory pyramidal neurons during early development. This node captures the single concept of the loss-of-function channel state and conforms to the shared epilepsy final common pathway.
Loss-of-Function / Later-Onset Model
Pyramidal (excitatory) neuron CL:0000598 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Pyramidal (excitatory) neuron, annotated with pyramidal neuron (CL:0000598). CL:0000598 is a cell type from the Cell Ontology.
Sodium ion transmembrane transport GO:0035725 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased Sodium ion transmembrane transport (GO:0035725). GO:0035725 is a biological process from the Gene Ontology. ↓ DECREASED
Downstream
Neuronal Hyperexcitability and Network Dysfunction Reduced excitatory-neuron firing dysregulates developing circuits and network excitability. Loss-of-Function / Later-Onset Model
Show evidence (1 reference)
PMID:28379373 SUPPORT In Vitro
"mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects"
Late-onset SCN2A forms with poor sodium-channel-blocker response show loss-of-function channel effects.
Neuronal Hyperexcitability and Network Dysfunction
Both arms converge on abnormal cortical network excitability - direct hyperexcitability in the gain-of-function arm, and developmental network dysfunction in the loss-of-function arm. This node captures the single concept of the resulting network dysfunction and conforms to the shared epilepsy final common pathway.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Downstream
Seizures and Developmental Encephalopathy Network dysfunction produces seizures and impaired development.
Show evidence (2 references)
PMID:34348148 SUPPORT Model Organism
"Here, we report the counterintuitive finding that severe NaV1.2 deficiency results in increased neuronal excitability."
Frames the convergent node: the loss-of-function arm does not simply reduce excitability but converges on the same abnormal network excitability as the gain-of-function arm.
PMID:34348148 SUPPORT Model Organism
"This unexpected neuronal hyperexcitability may serve as a cellular basis underlying NaV1.2 deficiency-related seizures."
Supports modeling this node as the proximate cellular substrate of seizures for both arms, including the loss-of-function arm.
Seizures and Developmental Encephalopathy
The clinical result is seizures (focal, tonic, epileptic spasms, and others, with age and arm-dependent semiology) together with developmental impairment; the loss-of-function arm is more associated with autism and intellectual disability. This node captures the single concept of the seizure/encephalopathy endpoint and conforms to the shared epilepsy final common pathway.
Neuron CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves Neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology.
Show evidence (2 references)
PMID:30813884 SUPPORT Human Clinical
"Deleterious variants in the voltage-gated sodium channel type 2 (Nav1.2) lead to a broad spectrum of phenotypes ranging from benign familial neonatal-infantile epilepsy (BFNIE), severe developmental and epileptic encephalopathy (DEE) and intellectual disability (ID) to autism spectrum disorders (ASD)."
Defines the clinical endpoint of the pathograph: seizures plus developmental impairment across a spectrum from benign epilepsy to DEE, intellectual disability, and autism.
PMID:31904126 SUPPORT Human Clinical
"There is increasing evidence that an important phenotype linked to the gene is autism and intellectual disability without epilepsy or with rare seizures in later childhood."
Supports the arm-dependence of the endpoint: the loss-of-function arm can present as autism and intellectual disability with little or no epilepsy.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for SCN2A-Related Developmental and Epileptic Encephalopathy Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

10
Focal Seizures HP:0007359 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Focal-onset seizure (HP:0007359). HP:0007359 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:28379373 SUPPORT Human Clinical
"Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy."
A 201-patient SCN2A series documents focal-seizure phenotypes (including epilepsy of infancy with migrating focal seizures).
PMID:28379373 SUPPORT Human Clinical
"focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients)"
Focal epilepsies were also identified as a distinct phenotype within the later-onset SCN2A group.
Epileptic Spasms HP:0011097 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Epileptic spasm (HP:0011097). HP:0011097 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28379373 SUPPORT Human Clinical
"West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children)"
West syndrome (infantile epileptic spasms syndrome) is reported as a common SCN2A phenotype, supporting epileptic spasms as a recognized feature.
Epileptic Encephalopathy HP:0200134 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Epileptic encephalopathy (HP:0200134). HP:0200134 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31904126 SUPPORT Human Clinical
"Phenotypes include benign (self-limited) neonatal and infantile epilepsy and more severe developmental and epileptic encephalopathies also presenting in early infancy."
Confirms developmental and epileptic encephalopathy as a core SCN2A phenotype presenting in early infancy.
Global Developmental Delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263). HP:0001263 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28256214 SUPPORT Human Clinical
"Variants in the SCN2A gene that disrupt the encoded neuronal sodium channel NaV1.2 are important risk factors for autism spectrum disorder (ASD), developmental delay, and infantile seizures."
Names developmental delay as one of the core phenotypes associated with disruptive SCN2A variants.
Intellectual Disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:31904126 SUPPORT Human Clinical
"other missense or truncating, loss of function variants present with later-onset epilepsies or intellectual disability only"
Ties intellectual disability specifically to the loss-of-function arm, as described for this phenotype.
PMID:30813884 SUPPORT Human Clinical
"complete loss-of-function variants lead to ID without seizures"
Patient-derived variants with complete loss of Nav1.2 function were found in individuals with intellectual disability and no seizures.
Autistic Behavior HP:0000729 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Autistic behavior (HP:0000729). HP:0000729 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:29691040 SUPPORT Human Clinical
"identified SCN2A dysfunction as a leading cause of infantile seizures, autism spectrum disorder, and intellectual disability"
SCN2A is established as a leading cause of autism spectrum disorder, supporting autistic behavior as a core phenotype.
PMID:28256214 SUPPORT In Vitro
"This functional characterization thus identifies SCN2A mutation and NaV1.2 dysfunction as the most frequently observed ASD risk factor detectable by exome sequencing"
Quantifies the strength of the autism association and links it to the loss-of-function arm characterized in the same study.
Migrating Focal Seizures HP:0032786 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Migrating focal seizure (HP:0032786). HP:0032786 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28379373 SUPPORT Human Clinical
"Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy."
A 201-patient SCN2A series lists epilepsy of infancy with migrating focal seizures among the recognized phenotypes of the disorder.
Continuous Spike and Waves During Slow Sleep HP:0031491 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Continuous spike and waves during slow sleep (HP:0031491). HP:0031491 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28379373 SUPPORT Human Clinical
"focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients)"
Six patients in the later-onset SCN2A group showed an electrical status epilepticus during slow sleep-like EEG pattern.
Generalized Myoclonic-Atonic Seizures HP:0011170 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized myoclonic-atonic seizure (HP:0011170). HP:0011170 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:28379373 SUPPORT Human Clinical
"distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients)"
Myoclonic-atonic epilepsy is reported as a distinct phenotype within the later-onset (loss-of-function) SCN2A group.
Neonatal Seizures HP:0032807 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neonatal seizure (HP:0032807). HP:0032807 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31904126 SUPPORT Human Clinical
"Phenotypes include benign (self-limited) neonatal and infantile epilepsy and more severe developmental and epileptic encephalopathies also presenting in early infancy."
Establishes neonatal-onset epilepsy as part of the SCN2A phenotypic spectrum, at both the self-limited and encephalopathic ends.
🧬

Genetic Associations

1
SCN2A
Gene: SCN2A hgnc:10588 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SCN2A (hgnc:10588). hgnc:10588 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: GERMLINE
Show evidence (1 reference)
PMID:28379373 SUPPORT Human Clinical
"truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers"
Truncating (loss-of-function) SCN2A mutations mapped exclusively to late-onset epilepsy with poor sodium-channel-blocker response.
💊

Medical Actions

3
Sodium-Channel-Blocking Antiseizure Medication
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: phenytoin CHEBI:8107 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses phenytoin (CHEBI:8107). CHEBI:8107 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Sodium-channel blockers (e.g., phenytoin, carbamazepine, oxcarbazepine, lacosamide) are often effective in the early-onset gain-of-function group by countering the increased sodium current, but can paradoxically worsen seizures in the later-onset loss-of-function group - making functional variant classification central to treatment.
Mechanism Target:
INHIBITS Increased Nav1.2 Sodium Current (Gain of Function) — Sodium-channel blockers reduce the increased Nav1.2 current in the gain-of-function arm.
Show evidence (2 references)
PMID:31904126 SUPPORT Human Clinical
"Sodium channel blockers may be effective antiepileptic medications in gain of function, neonatal and infantile presentations."
Explicitly matches the drug class to the gain-of-function mechanism node it targets.
PMID:28379373 SUPPORT Human Clinical
"a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function"
Links the degree of Nav1.2 gain of function to the clinical response to the inhibiting drug, supporting the mechanism-target relationship.
Show evidence (2 references)
PMID:28379373 SUPPORT Human Clinical
"the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months)"
Sodium-channel blockers reduced seizures or achieved freedom in early-infantile (gain-of-function) SCN2A epilepsy.
PMID:28379373 SUPPORT Human Clinical
"sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening"
In later-onset (loss-of-function) SCN2A epilepsy the same drugs were rarely effective and sometimes worsened seizures - the key precision caveat.
Broad-Spectrum Antiseizure Medication and Ketogenic Diet
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Broad-spectrum agents (e.g., levetiracetam, valproate, benzodiazepines) and the ketogenic diet are used, particularly in the later-onset loss-of-function group where sodium-channel blockers are avoided. Evidence for a specific non-sodium-channel-blocker regimen in SCN2A is limited; the rationale is largely the avoidance of sodium-channel blockade in the loss-of-function arm.
Show evidence (2 references)
PMID:28379373 SUPPORT Human Clinical
"sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening"
Provides the rationale for using non-sodium-channel-blocking agents in the later-onset (loss-of-function) group.
PMID:28379373 SUPPORT Human Clinical
"whereas other antiepileptic drugs were less effective"
Important caveat: in the early-infantile (gain-of-function) group, non-sodium-channel-blocking antiseizure drugs performed worse than sodium channel blockers, so this option is arm-specific rather than general.
Elsunersen (SCN2A-Directed Antisense Oligonucleotide)
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Platform: Antisense oligonucleotide RNase H knockdown
RNA target: SCN2A hgnc:10588 HUGO Gene Nomenclature Committee (hgnc) Relation: this treatment base-pairs with the transcript of this gene This treatment base-pairs with the transcript of SCN2A (hgnc:10588). hgnc:10588 is a gene from the HUGO Gene Nomenclature Committee. SCN2A mRNA
Elsunersen (PRAX-222) is an investigational antisense oligonucleotide that lowers SCN2A expression by RNase H-mediated transcript knockdown, designed for the gain-of-function, early-onset arm; it holds FDA Breakthrough Therapy designation and is in clinical trials.
Mechanism Target:
INHIBITS Increased Nav1.2 Sodium Current (Gain of Function) — Knocking down SCN2A lowers Nav1.2, countering the gain-of-function current.
Show evidence (1 reference)
PMID:34850743 SUPPORT Model Organism
"Biophysical gain of function in SCN2A is seen in some patients with early seizure onset developmental and epileptic encephalopathy (DEE). In these cases, targeted reduction in SCN2A expression could substantially improve clinical outcomes."
States the mechanism-target rationale: lowering SCN2A expression to counter the gain-of-function Nav1.2 node.
Show evidence (2 references)
PMID:34850743 SUPPORT Model Organism
"Administration of the ASO to Q/+ mice reduced spontaneous seizures and significantly extended life span."
Preclinical proof of concept for the RNase H gapmer ASO knockdown strategy that elsunersen (PRAX-222) implements in the gain-of-function arm.
PMID:34850743 SUPPORT Model Organism
"A human SCN2A gapmer ASO could likewise impact the lives of patients with SCN2A gain-of-function DEE."
Explicitly frames the human gapmer ASO (the elsunersen approach) as the translational target of this preclinical result; efficacy in patients is not yet established.
📊

Prevalence

2
Denmark
Birth Prevalence 1.3 per 100,000 1–9 per 100,000 (births)
Danish population data give a disease frequency of approximately 1/78,608 live births (~1.3 per 100,000). Estimates are strongly ascertainment-dependent and are rising with expanded genetic testing.
Show evidence (1 reference)
PMID:37776663 SUPPORT Human Clinical
"SCN2A gene pathogenic variants are associated with a wide phenotypic spectrum, encompassing epilepsy, developmental delay, and autism spectrum disorder. Researches conducted in Denmark have revealed a disease frequency of approximately 1/78,608 (0.0012%) live births in this population."
The Danish estimate of approximately one affected live birth in 78,608 concerns the broad SCN2A-related disease spectrum, including epilepsy, developmental delay and autism. It does not isolate developmental and epileptic encephalopathy alone.
Brescia province, Italy
Birth Prevalence 4.7 per 100,000 1–9 per 100,000 (births)
A regional Italian birth-cohort study (Brescia, 2002-2021) found 11 SCN2A cases among 232,678 live births (0.0047%, ~4.7 per 100,000) - about three to four times the Danish estimate, illustrating how ascertainment and testing practice drive these figures.
Show evidence (2 references)
PMID:37776663 SUPPORT Human Clinical
"A frequency of 11/23,2678 births (0.0047%) was found."
Reports the Brescia regional birth frequency of SCN2A-related disorder.
PMID:37776663 SUPPORT Human Clinical
"More studies are needed to further delineate the frequency of SCN2A pathogenic variant in Italian population."
The authors themselves flag the uncertainty of these ascertainment-limited frequency estimates.
🔬

Clinical Trials

1
NCT05737784 PHASE_I RECRUITING
EMBRAVE: a seamless Phase 1/2 trial of the SCN2A-directed antisense oligonucleotide PRAX-222 (elsunersen) in children with early-onset (gain-of-function) SCN2A-DEE.
Target Phenotypes: Focal-onset seizure HP:0007359 Human Phenotype Ontology (HP) Relation: this clinical trial targets this phenotype This clinical trial targets Focal-onset seizure (HP:0007359). HP:0007359 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
clinicaltrials:NCT05737784 SUPPORT
"The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy"
A clinical trial of the SCN2A-directed ASO PRAX-222 (elsunersen) in early-onset (gain-of-function) SCN2A-DEE, the mechanism-matched precision therapy.
{ }

Source YAML

click to show 
name: SCN2A-Related Developmental and Epileptic Encephalopathy
creation_date: "2026-07-18T00:00:00Z"
category: Genetic
description: >-
  SCN2A-related developmental and epileptic encephalopathy (DEE11) is caused by
  pathogenic variants in SCN2A, which encodes the voltage-gated sodium channel
  Nav1.2. The disorder has a striking mechanistic dichotomy with opposite
  treatment implications. Gain-of-function variants increase Nav1.2 sodium
  current and typically produce early-infantile-onset (usually before three
  months) epilepsy that often responds to sodium-channel-blocking drugs.
  Loss-of-function variants reduce Nav1.2 current and typically produce
  later-onset (after three months) epilepsy and/or autism and intellectual
  disability, in which sodium-channel blockers can paradoxically worsen
  seizures. Determining the functional consequence of the variant is therefore
  central to management.
parents:
- Epilepsy
- Neurological Disease
synonyms:
- DEE11
- SCN2A encephalopathy
- SCN2A-related epilepsy
disease_term:
  preferred_term: developmental and epileptic encephalopathy, 11
  term:
    id: MONDO:0013388
    label: developmental and epileptic encephalopathy, 11
mappings:
  mondo_mappings:
  - term:
      id: MONDO:0013388
      label: developmental and epileptic encephalopathy, 11
    mapping_predicate: skos:exactMatch
    mapping_source: MONDO
    mapping_justification: >-
      MONDO:0013388 is the SCN2A developmental and epileptic encephalopathy
      (DEE11) concept.
classifications:
  channelopathy_category:
    classification_value: neurological channelopathy
    evidence:
    - reference: PMID:28379373
      reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders."
      explanation: >-
        The disease gene encodes a voltage-gated sodium channel (Nav1.2) whose
        dysfunction produces a CNS phenotype, placing this disorder in the
        neurological channelopathy organ-system group.
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:28379373
      reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Mutations in SCN2A, a gene encoding the voltage-gated sodium channel Nav1.2, have been associated with a spectrum of epilepsies and neurodevelopmental disorders."
      explanation: >-
        The disorder presents as an epilepsy and neurodevelopmental syndrome,
        whose clinical home is the neurologic Part.
  - classification_value: GENETICS_ENVIRONMENT_DISEASE
    evidence:
    - reference: PMID:28379373
      reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Our clinical and experimental data suggest a correlation between age at disease onset, response to sodium channel blockers and the functional properties of mutations in children with SCN2A-related epilepsy."
      explanation: >-
        This is a monogenic disorder in which the functional consequence of the
        individual SCN2A variant determines phenotype and drug response, so the
        Mendelian-genetics Part applies in addition to the neurologic one.
    notes: >-
      Unlike the polygenic idiopathic generalized epilepsies, SCN2A-DEE is a
      single-gene, autosomal dominant (usually de novo) disorder, so a genetic
      Part is a substantive rather than nominal assignment here.
inheritance:
- name: Autosomal dominant (de novo)
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    SCN2A-DEE is autosomal dominant; the great majority of variants are de novo.
    Recurrence risk to siblings is low but not zero (on the order of 1-2%)
    because of the possibility of parental germline (or low-level somatic)
    mosaicism.
  evidence:
  - reference: PMID:34859793
    reference_title: "Phenotypic spectrum and long-term outcome of children with genetic early-infantile-onset developmental and epileptic encephalopathy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "With regards to inheritance pattern, de novo heterozygous mutations accounted for the majority (104/118; 88.1%)"
    explanation: >-
      In a genetically diagnosed early-infantile-onset DEE cohort (which included
      SCN2A cases), de novo heterozygous variants accounted for the large
      majority, supporting the de novo autosomal dominant mode of inheritance.
  - reference: PMID:31077350
    reference_title: "Parental mosaicism in epilepsies due to alleged de novo variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Parental mosaicism was observed in the following genes: SCN1A, SCN2A, SCN8A, and STXBP1."
    explanation: >-
      Documents parental somatic mosaicism for SCN2A variants that appeared de
      novo, the basis for the small but non-zero sibling recurrence risk.
  - reference: PMID:31077350
    reference_title: "Parental mosaicism in epilepsies due to alleged de novo variants."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "parents affected by low-grade mosaicism are faced with an increased recurrence risk for transmitting the pathogenic variant, compared to the overall recurrence risk for a second affected child estimated at approximately 1%"
    explanation: >-
      Quantifies the baseline sibling recurrence risk (~1%) and the mosaicism
      mechanism that raises it in individual families.
mechanistic_hypotheses:
- hypothesis_group_id: scn2a_gain_of_function_early_onset
  hypothesis_label: Gain-of-Function / Early-Onset Model
  status: CANONICAL
  description: >-
    Gain-of-function SCN2A variants increase Nav1.2 sodium current and neuronal
    excitability, producing early-infantile-onset epilepsy (typically before
    three months of age) that often responds to sodium-channel-blocking drugs.
  evidence:
  - reference: PMID:31904126
    reference_title: "Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Some missense, gain of function variants tend to present in early infancy with epilepsy"
    explanation: >-
      States the gain-of-function / early-infantile-onset arm of the SCN2A
      dichotomy that this hypothesis group models.
  - reference: PMID:28256214
    reference_title: "Opposing Effects on Na(V)1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Variants observed in infantile seizures are predominantly missense, leading to a gain of function and increased neuronal excitability."
    explanation: >-
      Voltage-clamp characterization links infantile-seizure SCN2A variants to
      gain of Nav1.2 function and increased neuronal excitability.
- hypothesis_group_id: scn2a_loss_of_function_later_onset
  hypothesis_label: Loss-of-Function / Later-Onset Model
  status: CANONICAL
  description: >-
    Loss-of-function SCN2A variants reduce Nav1.2 current, impairing action
    potential firing in excitatory neurons, and typically produce later-onset
    (after three months) epilepsy and/or autism and intellectual disability, in
    which sodium-channel blockers can worsen seizures.
  evidence:
  - reference: PMID:37578743
    reference_title: "Epilepsy-associated SCN2A (NaV1.2) variants exhibit diverse and complex functional properties."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "predominantly gain-of-function variants cause neonatal-onset epilepsy, whereas loss-of-function variants are associated with ASD and ID"
    explanation: >-
      States the loss-of-function arm (autism and intellectual disability) of the
      SCN2A functional dichotomy modeled by this hypothesis group.
  - reference: PMID:28256214
    reference_title: "Opposing Effects on Na(V)1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "In contrast to gain of function variants that contribute to seizure, we found that all ASD-associated variants dampened or eliminated channel function."
    explanation: >-
      Direct electrophysiological demonstration that autism-associated SCN2A
      variants reduce or abolish Nav1.2 function.
  - reference: PMID:37578743
    reference_title: "Epilepsy-associated SCN2A (NaV1.2) variants exhibit diverse and complex functional properties."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Many epilepsy-associated variants in our study exhibited complex patterns of gain- and loss-of-functions that are difficult to classify by a simple binary scheme."
    explanation: >-
      Important caveat: high-throughput automated patch-clamp shows many variants
      have mixed gain/loss features, so the two-arm model is a useful
      simplification rather than a strict binary.
pathophysiology:
- name: SCN2A Variant (Nav1.2 Dysfunction)
  description: >-
    A pathogenic variant in SCN2A alters the function of the voltage-gated
    sodium channel Nav1.2. This node captures the single concept of the
    initiating channel lesion, whose functional direction (gain versus loss of
    function) sets the clinical arm.
  role: trigger
  gene:
    preferred_term: SCN2A
    term:
      id: hgnc:10588
      label: SCN2A
  molecular_functions:
  - preferred_term: voltage-gated sodium channel activity
    term:
      id: GO:0005248
      label: voltage-gated sodium channel activity
  evidence:
  - reference: PMID:29691040
    reference_title: "Progress in Understanding and Treating SCN2A-Mediated Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Advances in gene discovery for neurodevelopmental disorders have identified SCN2A dysfunction as a leading cause of infantile seizures, autism spectrum disorder, and intellectual disability. SCN2A encodes the neuronal sodium channel NaV1.2."
    explanation: >-
      Establishes the initiating lesion of this entry: SCN2A variants disrupting
      the neuronal sodium channel Nav1.2 as a leading cause of infantile
      seizures and neurodevelopmental disease.
  - reference: PMID:29691040
    reference_title: "Progress in Understanding and Treating SCN2A-Mediated Disorders."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Functional assays demonstrate strong correlation between genotype and phenotype."
    explanation: >-
      Supports the modeling choice that the functional direction of the variant
      (gain versus loss of function) is what sets the clinical arm. The
      genotype-phenotype correlation is established by in vitro functional
      (electrophysiological) characterization of the variants.
  downstream:
  - target: Increased Nav1.2 Sodium Current (Gain of Function)
    causal_link_type: DIRECT
    description: >-
      Gain-of-function variants increase Nav1.2 sodium current.
    hypothesis_groups:
    - scn2a_gain_of_function_early_onset
    evidence:
    - reference: PMID:30813884
      reference_title: "Further corroboration of distinct functional features in SCN2A variants causing intellectual disability or epileptic phenotypes."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "small gain-of-function variants cause BFNIE and EE variants exhibit variable but profound Nav1.2 gating changes"
      explanation: >-
        Whole-cell patch-clamp of patient variants links epilepsy-associated
        SCN2A alleles to gain of Nav1.2 channel function.
  - target: Decreased Nav1.2 Sodium Current (Loss of Function)
    causal_link_type: DIRECT
    description: >-
      Loss-of-function variants reduce Nav1.2 sodium current.
    hypothesis_groups:
    - scn2a_loss_of_function_later_onset
    evidence:
    - reference: PMID:30813884
      reference_title: "Further corroboration of distinct functional features in SCN2A variants causing intellectual disability or epileptic phenotypes."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "The three variants identified in ID patients without seizures, p.R937C, p.L611Vfs*35 and p.W1716*, did not produce measurable currents."
      explanation: >-
        Variants from intellectual-disability patients produced no measurable
        sodium current, i.e. loss of Nav1.2 function.
- name: Increased Nav1.2 Sodium Current (Gain of Function)
  description: >-
    Gain-of-function variants increase the Nav1.2 sodium current (through
    enhanced activation, impaired inactivation, or increased persistent
    current), directly raising neuronal excitability. This node captures the
    single concept of the gain-of-function channel state and conforms to the
    shared epilepsy final common pathway.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  biological_processes:
  - preferred_term: Sodium ion transmembrane transport
    term:
      id: GO:0035725
      label: sodium ion transmembrane transport
    modifier: INCREASED
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "mutations associated with early infantile epilepsy result in increased sodium channel activity with gain-of-function"
    explanation: >-
      Functional studies show early-infantile-epilepsy SCN2A mutations increase
      sodium channel activity (gain of function).
  downstream:
  - target: Neuronal Hyperexcitability and Network Dysfunction
    causal_link_type: DIRECT
    description: >-
      Increased sodium current directly raises neuronal excitability.
    hypothesis_groups:
    - scn2a_gain_of_function_early_onset
    evidence:
    - reference: PMID:28256214
      reference_title: "Opposing Effects on Na(V)1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "leading to a gain of function and increased neuronal excitability"
      explanation: >-
        Directly links increased Nav1.2 function to increased neuronal
        excitability, the causal step modeled by this edge.
- name: Decreased Nav1.2 Sodium Current (Loss of Function)
  description: >-
    Loss-of-function variants reduce the Nav1.2 sodium current, impairing action
    potential initiation and propagation especially in excitatory pyramidal
    neurons during early development. This node captures the single concept of
    the loss-of-function channel state and conforms to the shared epilepsy final
    common pathway.
  role: mediator
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Ion Channel and Synaptic Dysfunction"
  cell_types:
  - preferred_term: Pyramidal (excitatory) neuron
    term:
      id: CL:0000598
      label: pyramidal neuron
  biological_processes:
  - preferred_term: Sodium ion transmembrane transport
    term:
      id: GO:0035725
      label: sodium ion transmembrane transport
    modifier: DECREASED
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "mutations in patients with late-onset forms and an insufficient response to sodium channel blockers were associated with loss-of-function effects"
    explanation: >-
      Late-onset SCN2A forms with poor sodium-channel-blocker response show
      loss-of-function channel effects.
  downstream:
  - target: Neuronal Hyperexcitability and Network Dysfunction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: >-
      Reduced excitatory-neuron firing dysregulates developing circuits and
      network excitability.
    hypothesis_groups:
    - scn2a_loss_of_function_later_onset
    evidence:
    - reference: PMID:31230762
      reference_title: "The Autism-Associated Gene Scn2a Contributes to Dendritic Excitability and Synaptic Function in the Prefrontal Cortex."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "NaV1.2 loss reduced action potential backpropagation into dendrites, impairing synaptic plasticity and synaptic strength"
      explanation: >-
        Shows the intermediate steps by which reduced Nav1.2 current
        dysregulates cortical circuits (dendritic excitability and synaptic
        function) rather than acting through simple firing loss alone.
    - reference: PMID:34348148
      reference_title: "Severe deficiency of the voltage-gated sodium channel Na(V)1.2 elevates neuronal excitability in adult mice."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Using a NaV1.2-deficient mouse model, we show enhanced intrinsic excitability of principal neurons in the prefrontal cortex and striatum, brain regions known to be involved in Scn2a-related seizures."
      explanation: >-
        Demonstrates that severe Nav1.2 deficiency can paradoxically produce
        network hyperexcitability, the counter-intuitive link this edge encodes.
- name: Neuronal Hyperexcitability and Network Dysfunction
  description: >-
    Both arms converge on abnormal cortical network excitability - direct
    hyperexcitability in the gain-of-function arm, and developmental network
    dysfunction in the loss-of-function arm. This node captures the single
    concept of the resulting network dysfunction and conforms to the shared
    epilepsy final common pathway.
  role: central_effector
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:34348148
    reference_title: "Severe deficiency of the voltage-gated sodium channel Na(V)1.2 elevates neuronal excitability in adult mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Here, we report the counterintuitive finding that severe NaV1.2 deficiency results in increased neuronal excitability."
    explanation: >-
      Frames the convergent node: the loss-of-function arm does not simply
      reduce excitability but converges on the same abnormal network
      excitability as the gain-of-function arm.
  - reference: PMID:34348148
    reference_title: "Severe deficiency of the voltage-gated sodium channel Na(V)1.2 elevates neuronal excitability in adult mice."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "This unexpected neuronal hyperexcitability may serve as a cellular basis underlying NaV1.2 deficiency-related seizures."
    explanation: >-
      Supports modeling this node as the proximate cellular substrate of
      seizures for both arms, including the loss-of-function arm.
  downstream:
  - target: Seizures and Developmental Encephalopathy
    causal_link_type: DIRECT
    description: >-
      Network dysfunction produces seizures and impaired development.
    evidence:
    - reference: PMID:34850743
      reference_title: "Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Untreated Q/+ mice presented with spontaneous seizures at P1 and did not survive beyond P30."
      explanation: >-
        In a knock-in model of an SCN2A gain-of-function DEE variant, the
        resulting excitability change produces spontaneous seizures and early
        death, the clinical endpoint this edge encodes.
- name: Seizures and Developmental Encephalopathy
  description: >-
    The clinical result is seizures (focal, tonic, epileptic spasms, and others,
    with age and arm-dependent semiology) together with developmental
    impairment; the loss-of-function arm is more associated with autism and
    intellectual disability. This node captures the single concept of the
    seizure/encephalopathy endpoint and conforms to the shared epilepsy final
    common pathway.
  role: consequence
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Recurrent Unprovoked Seizures"
  cell_types:
  - preferred_term: Neuron
    term:
      id: CL:0000540
      label: neuron
  evidence:
  - reference: PMID:30813884
    reference_title: "Further corroboration of distinct functional features in SCN2A variants causing intellectual disability or epileptic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Deleterious variants in the voltage-gated sodium channel type 2 (Nav1.2) lead to a broad spectrum of phenotypes ranging from benign familial neonatal-infantile epilepsy (BFNIE), severe developmental and epileptic encephalopathy (DEE) and intellectual disability (ID) to autism spectrum disorders (ASD)."
    explanation: >-
      Defines the clinical endpoint of the pathograph: seizures plus
      developmental impairment across a spectrum from benign epilepsy to DEE,
      intellectual disability, and autism.
  - reference: PMID:31904126
    reference_title: "Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "There is increasing evidence that an important phenotype linked to the gene is autism and intellectual disability without epilepsy or with rare seizures in later childhood."
    explanation: >-
      Supports the arm-dependence of the endpoint: the loss-of-function arm can
      present as autism and intellectual disability with little or no epilepsy.
phenotypes:
- name: Focal Seizures
  description: >-
    Focal-onset seizures occur across the SCN2A spectrum. In the early-onset
    group they present as epilepsy of infancy with migrating focal seizures; in
    the late-onset group as focal epilepsies with an electrical status
    epilepticus during slow sleep-like EEG pattern.
  phenotype_term:
    preferred_term: Focal-onset seizure
    term:
      id: HP:0007359
      label: Focal-onset seizure
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy."
    explanation: >-
      A 201-patient SCN2A series documents focal-seizure phenotypes (including
      epilepsy of infancy with migrating focal seizures).
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients)"
    explanation: >-
      Focal epilepsies were also identified as a distinct phenotype within the
      later-onset SCN2A group.
- name: Epileptic Spasms
  description: >-
    Epileptic spasms occur in a subset of patients.
  phenotype_term:
    preferred_term: Epileptic spasm
    term:
      id: HP:0011097
      label: Epileptic spasm
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "West syndrome constitutes a common phenotype with a major recurring mutation (p.Arg853Gln: two new and four previously reported children)"
    explanation: >-
      West syndrome (infantile epileptic spasms syndrome) is reported as a common
      SCN2A phenotype, supporting epileptic spasms as a recognized feature.
- name: Epileptic Encephalopathy
  description: >-
    The epilepsy is accompanied by a developmental and epileptic encephalopathy.
  phenotype_term:
    preferred_term: Epileptic encephalopathy
    term:
      id: HP:0200134
      label: Epileptic encephalopathy
  evidence:
  - reference: PMID:31904126
    reference_title: "Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenotypes include benign (self-limited) neonatal and infantile epilepsy and more severe developmental and epileptic encephalopathies also presenting in early infancy."
    explanation: >-
      Confirms developmental and epileptic encephalopathy as a core SCN2A
      phenotype presenting in early infancy.
- name: Global Developmental Delay
  description: >-
    Global developmental delay and intellectual disability are typical,
    particularly in the loss-of-function group.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
  evidence:
  - reference: PMID:28256214
    reference_title: "Opposing Effects on Na(V)1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Variants in the SCN2A gene that disrupt the encoded neuronal sodium channel NaV1.2 are important risk factors for autism spectrum disorder (ASD), developmental delay, and infantile seizures."
    explanation: >-
      Names developmental delay as one of the core phenotypes associated with
      disruptive SCN2A variants.
- name: Intellectual Disability
  description: >-
    Intellectual disability is typical, particularly in the loss-of-function
    group, and can be severe.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:31904126
    reference_title: "Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "other missense or truncating, loss of function variants present with later-onset epilepsies or intellectual disability only"
    explanation: >-
      Ties intellectual disability specifically to the loss-of-function arm, as
      described for this phenotype.
  - reference: PMID:30813884
    reference_title: "Further corroboration of distinct functional features in SCN2A variants causing intellectual disability or epileptic phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "complete loss-of-function variants lead to ID without seizures"
    explanation: >-
      Patient-derived variants with complete loss of Nav1.2 function were found
      in individuals with intellectual disability and no seizures.
- name: Autistic Behavior
  description: >-
    Autism spectrum features are strongly associated with the loss-of-function
    group, sometimes without prominent epilepsy.
  phenotype_term:
    preferred_term: Autistic behavior
    term:
      id: HP:0000729
      label: Autistic behavior
  evidence:
  - reference: PMID:29691040
    reference_title: "Progress in Understanding and Treating SCN2A-Mediated Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "identified SCN2A dysfunction as a leading cause of infantile seizures, autism spectrum disorder, and intellectual disability"
    explanation: >-
      SCN2A is established as a leading cause of autism spectrum disorder,
      supporting autistic behavior as a core phenotype.
  - reference: PMID:28256214
    reference_title: "Opposing Effects on Na(V)1.2 Function Underlie Differences Between SCN2A Variants Observed in Individuals With Autism Spectrum Disorder or Infantile Seizures."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This functional characterization thus identifies SCN2A mutation and NaV1.2 dysfunction as the most frequently observed ASD risk factor detectable by exome sequencing"
    explanation: >-
      Quantifies the strength of the autism association and links it to the
      loss-of-function arm characterized in the same study.
- name: Migrating Focal Seizures
  description: >-
    Epilepsy of infancy with migrating focal seizures (EIMFS) is one of the
    recognized early-onset SCN2A epilepsy syndromes.
  phenotype_term:
    preferred_term: Migrating focal seizure
    term:
      id: HP:0032786
      label: Migrating focal seizure
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Other known phenotypes include Ohtahara syndrome, epilepsy of infancy with migrating focal seizures, and intellectual disability or autism without epilepsy."
    explanation: >-
      A 201-patient SCN2A series lists epilepsy of infancy with migrating focal
      seizures among the recognized phenotypes of the disorder.
- name: Continuous Spike and Waves During Slow Sleep
  description: >-
    An electrical status epilepticus in sleep (ESES)-like EEG pattern was
    documented in a subset of the later-onset group.
  phenotype_term:
    preferred_term: Continuous spike and waves during slow sleep
    term:
      id: HP:0031491
      label: Continuous spike and waves during slow sleep
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "focal epilepsies with an electrical status epilepticus during slow sleep-like EEG pattern (six patients)"
    explanation: >-
      Six patients in the later-onset SCN2A group showed an electrical status
      epilepticus during slow sleep-like EEG pattern.
- name: Generalized Myoclonic-Atonic Seizures
  description: >-
    Myoclonic-atonic epilepsy is one of the distinct phenotypes seen within the
    later-onset SCN2A group.
  phenotype_term:
    preferred_term: Generalized myoclonic-atonic seizure
    term:
      id: HP:0011170
      label: Generalized myoclonic-atonic seizure
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "distinct phenotypes can be seen within the late onset group, including myoclonic-atonic epilepsy (two patients)"
    explanation: >-
      Myoclonic-atonic epilepsy is reported as a distinct phenotype within the
      later-onset (loss-of-function) SCN2A group.
- name: Neonatal Seizures
  description: >-
    Seizures with neonatal onset occur in the early-onset, gain-of-function arm,
    spanning self-limited neonatal epilepsy through severe encephalopathy.
  phenotype_term:
    preferred_term: Neonatal seizure
    term:
      id: HP:0032807
      label: Neonatal seizure
  evidence:
  - reference: PMID:31904126
    reference_title: "Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Phenotypes include benign (self-limited) neonatal and infantile epilepsy and more severe developmental and epileptic encephalopathies also presenting in early infancy."
    explanation: >-
      Establishes neonatal-onset epilepsy as part of the SCN2A phenotypic
      spectrum, at both the self-limited and encephalopathic ends.
prevalence:
- population: Denmark
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 1.3
  notes: >-
    Danish population data give a disease frequency of approximately 1/78,608
    live births (~1.3 per 100,000). Estimates are strongly
    ascertainment-dependent and are rising with expanded genetic testing.
  evidence:
  - reference: PMID:37776663
    reference_title: "Frequency of SCN2A-related disorder in the regional epilepsy centre of brescia between 2002 and 2021."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      SCN2A gene pathogenic variants are associated with a wide phenotypic spectrum, encompassing
      epilepsy, developmental delay, and autism spectrum disorder. Researches conducted in Denmark
      have revealed a disease frequency of approximately 1/78,608 (0.0012%) live births in this
      population.
    explanation: >-
      The Danish estimate of approximately one affected live birth in 78,608 concerns the broad
      SCN2A-related disease spectrum, including epilepsy, developmental delay and autism. It does
      not isolate developmental and epileptic encephalopathy alone.
- population: Brescia province, Italy
  measure_type: BIRTH_PREVALENCE
  prevalence_class: BAND_1_9_PER_100000
  rate_per_100000: 4.7
  notes: >-
    A regional Italian birth-cohort study (Brescia, 2002-2021) found 11 SCN2A
    cases among 232,678 live births (0.0047%, ~4.7 per 100,000) - about three to
    four times the Danish estimate, illustrating how ascertainment and testing
    practice drive these figures.
  evidence:
  - reference: PMID:37776663
    reference_title: "Frequency of SCN2A-related disorder in the regional epilepsy centre of brescia between 2002 and 2021."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A frequency of 11/23,2678 births (0.0047%) was found."
    explanation: >-
      Reports the Brescia regional birth frequency of SCN2A-related disorder.
  - reference: PMID:37776663
    reference_title: "Frequency of SCN2A-related disorder in the regional epilepsy centre of brescia between 2002 and 2021."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "More studies are needed to further delineate the frequency of SCN2A pathogenic variant in Italian population."
    explanation: >-
      The authors themselves flag the uncertainty of these ascertainment-limited
      frequency estimates.
genetic:
- name: SCN2A
  gene_term:
    preferred_term: SCN2A
    term:
      id: hgnc:10588
      label: SCN2A
  relationship_type: CAUSATIVE
  variant_origin: GERMLINE
  notes: >-
    SCN2A encodes the voltage-gated sodium channel Nav1.2. Most DEE variants are
    de novo. The functional consequence is genotype-dependent: gain-of-function
    variants cause early-onset (typically before three months) seizures
    responsive to sodium-channel blockers, whereas loss-of-function variants
    cause later-onset epilepsy and/or autism in which sodium-channel blockers
    can worsen seizures.
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "truncating mutations were exclusively seen in patients with late onset epilepsies and lack of response to sodium channel blockers"
    explanation: >-
      Truncating (loss-of-function) SCN2A mutations mapped exclusively to
      late-onset epilepsy with poor sodium-channel-blocker response.
treatments:
- name: Sodium-Channel-Blocking Antiseizure Medication
  description: >-
    Sodium-channel blockers (e.g., phenytoin, carbamazepine, oxcarbazepine,
    lacosamide) are often effective in the early-onset gain-of-function group by
    countering the increased sodium current, but can paradoxically worsen
    seizures in the later-onset loss-of-function group - making functional
    variant classification central to treatment.
  therapeutic_modality: SMALL_MOLECULE
  target_mechanisms:
  - target: Increased Nav1.2 Sodium Current (Gain of Function)
    treatment_effect: INHIBITS
    description: >-
      Sodium-channel blockers reduce the increased Nav1.2 current in the
      gain-of-function arm.
    evidence:
    - reference: PMID:31904126
      reference_title: "Phenotypic spectrum and genetics of SCN2A-related disorders, treatment options, and outcomes in epilepsy and beyond."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Sodium channel blockers may be effective antiepileptic medications in gain of function, neonatal and infantile presentations."
      explanation: >-
        Explicitly matches the drug class to the gain-of-function mechanism node
        it targets.
    - reference: PMID:28379373
      reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "a good response to sodium channel blockers clinically was found to be associated with a relatively small gain-of-function"
      explanation: >-
        Links the degree of Nav1.2 gain of function to the clinical response to
        the inhibiting drug, supporting the mechanism-target relationship.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: phenytoin
      term:
        id: CHEBI:8107
        label: phenytoin
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the use of sodium channel blockers was often associated with clinically relevant seizure reduction or seizure freedom in children with early infantile epilepsies (<3 months)"
    explanation: >-
      Sodium-channel blockers reduced seizures or achieved freedom in
      early-infantile (gain-of-function) SCN2A epilepsy.
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening"
    explanation: >-
      In later-onset (loss-of-function) SCN2A epilepsy the same drugs were
      rarely effective and sometimes worsened seizures - the key precision
      caveat.
- name: Broad-Spectrum Antiseizure Medication and Ketogenic Diet
  description: >-
    Broad-spectrum agents (e.g., levetiracetam, valproate, benzodiazepines) and
    the ketogenic diet are used, particularly in the later-onset loss-of-function
    group where sodium-channel blockers are avoided. Evidence for a specific
    non-sodium-channel-blocker regimen in SCN2A is limited; the rationale is
    largely the avoidance of sodium-channel blockade in the loss-of-function arm.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening"
    explanation: >-
      Provides the rationale for using non-sodium-channel-blocking agents in the
      later-onset (loss-of-function) group.
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "whereas other antiepileptic drugs were less effective"
    explanation: >-
      Important caveat: in the early-infantile (gain-of-function) group,
      non-sodium-channel-blocking antiseizure drugs performed worse than sodium
      channel blockers, so this option is arm-specific rather than general.
- name: Elsunersen (SCN2A-Directed Antisense Oligonucleotide)
  description: >-
    Elsunersen (PRAX-222) is an investigational antisense oligonucleotide that
    lowers SCN2A expression by RNase H-mediated transcript knockdown, designed
    for the gain-of-function, early-onset arm; it holds FDA Breakthrough Therapy
    designation and is in clinical trials.
  therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE
  oligonucleotide_details:
    oligonucleotide_mechanism: RNASE_H_KNOCKDOWN
    target_gene:
      preferred_term: SCN2A
      term:
        id: hgnc:10588
        label: SCN2A
    target_transcript: SCN2A mRNA
  target_mechanisms:
  - target: Increased Nav1.2 Sodium Current (Gain of Function)
    treatment_effect: INHIBITS
    description: >-
      Knocking down SCN2A lowers Nav1.2, countering the gain-of-function current.
    evidence:
    - reference: PMID:34850743
      reference_title: "Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Biophysical gain of function in SCN2A is seen in some patients with early seizure onset developmental and epileptic encephalopathy (DEE). In these cases, targeted reduction in SCN2A expression could substantially improve clinical outcomes."
      explanation: >-
        States the mechanism-target rationale: lowering SCN2A expression to
        counter the gain-of-function Nav1.2 node.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
  evidence:
  - reference: PMID:34850743
    reference_title: "Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Administration of the ASO to Q/+ mice reduced spontaneous seizures and significantly extended life span."
    explanation: >-
      Preclinical proof of concept for the RNase H gapmer ASO knockdown strategy
      that elsunersen (PRAX-222) implements in the gain-of-function arm.
  - reference: PMID:34850743
    reference_title: "Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "A human SCN2A gapmer ASO could likewise impact the lives of patients with SCN2A gain-of-function DEE."
    explanation: >-
      Explicitly frames the human gapmer ASO (the elsunersen approach) as the
      translational target of this preclinical result; efficacy in patients is
      not yet established.
clinical_trials:
- name: NCT05737784
  phase: PHASE_I
  status: RECRUITING
  description: >-
    EMBRAVE: a seamless Phase 1/2 trial of the SCN2A-directed antisense
    oligonucleotide PRAX-222 (elsunersen) in children with early-onset
    (gain-of-function) SCN2A-DEE.
  target_phenotypes:
  - preferred_term: Focal-onset seizure
    term:
      id: HP:0007359
      label: Focal-onset seizure
  evidence:
  - reference: clinicaltrials:NCT05737784
    reference_title: "A Seamless, Clinical Trial to Investigate the Safety and Efficacy of Multiple Doses of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy"
    supports: SUPPORT
    snippet: "The goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy"
    explanation: >-
      A clinical trial of the SCN2A-directed ASO PRAX-222 (elsunersen) in
      early-onset (gain-of-function) SCN2A-DEE, the mechanism-matched precision
      therapy.
datasets: []
discussions:
- discussion_id: scn2a-functional-classification-for-treatment
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - "pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)"
  - "pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)"
  prompt: >-
    Because sodium-channel blockers help gain-of-function SCN2A epilepsy but can
    worsen loss-of-function forms, treatment hinges on knowing the functional
    consequence of a variant. How reliably can gain versus loss of function be
    inferred at the bedside from age at onset (before versus after three months)
    and variant type, and how quickly can functional assays resolve ambiguous
    (e.g., missense, VUS) variants to guide drug choice?
  rationale: >-
    Onset age and truncating status are useful proxies but not perfect, and many
    missense variants are of uncertain effect; a wrong inference can select a
    drug that worsens seizures. A fast, validated functional-classification
    pathway would directly change management.
  evidence:
  - reference: PMID:28379373
    reference_title: "Genetic and phenotypic heterogeneity suggest therapeutic implications in SCN2A-related disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "sodium channel blockers were rarely effective in epilepsies with later onset (≥3 months) and sometimes induced seizure worsening"
    explanation: >-
      Demonstrates the opposite treatment response by arm, motivating rapid
      functional classification.
  proposed_experiments:
  - experiment_id: scn2a-functional-assay-pipeline
    name: Rapid functional-classification pipeline
    description: >-
      Benchmark high-throughput electrophysiology and predictive models against
      clinical response to sodium-channel blockers across a large SCN2A variant
      set to establish a rapid gain/loss classification that guides therapy.
    readouts:
    - name: Predicted gain/loss versus clinical drug response
      target: "pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)"
    decision_criterion: >-
      A classifier that predicts drug response better than onset age alone would
      support its clinical use.
    would_support:
    - "pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)"
    - "pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)"
- discussion_id: scn2a-precision-therapy-aso
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - "pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)"
  prompt: >-
    Antisense-oligonucleotide and other gene-directed strategies that lower or
    raise Nav1.2 are in development for SCN2A disorders. Can allele- or
    direction-specific approaches safely correct the gain-of-function arm
    (lowering Nav1.2) and the loss-of-function arm (raising Nav1.2) without
    tipping the opposite way, and in what developmental window must they act?
  rationale: >-
    Because the two arms need opposite corrections, a one-size intervention is
    unsafe; the therapeutic window and the reversibility of the encephalopathy
    once established are open questions central to precision therapy.
  evidence:
  - reference: PMID:34850743
    reference_title: "Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Across a range of behavioral tests, Scn2a ASO-treated Q/+ mice were largely indistinguishable from WT mice, suggesting treatment is well tolerated."
    explanation: >-
      Shows that direction-specific Nav1.2 lowering was tolerated in a
      gain-of-function model, the starting point for the open question of whether
      such approaches are safe without tipping toward the opposite arm.
  - reference: PMID:29691040
    reference_title: "Progress in Understanding and Treating SCN2A-Mediated Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "raises the possibility that ligands that selectively enhance or diminish channel function may improve symptoms"
    explanation: >-
      Frames the direction-specific therapeutic strategy (enhancing versus
      diminishing Nav1.2) that this knowledge gap interrogates.
  proposed_experiments:
  - experiment_id: scn2a-directional-therapy-model
    name: Direction-specific Nav1.2 modulation study
    description: >-
      Test gain-lowering (e.g., ASO knockdown) and loss-restoring approaches in
      genotype-matched SCN2A models across developmental stages, measuring
      seizure, network, and behavioral outcomes and off-target excitability.
    readouts:
    - name: Outcome of directional Nav1.2 modulation by arm and timing
      target: "pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)"
    would_support:
    - "pathophysiology#Increased Nav1.2 Sodium Current (Gain of Function)"
- discussion_id: scn2a-lof-autism-mechanism
  kind: KNOWLEDGE_GAP
  status: OPEN
  attaches_to:
  - "pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)"
  prompt: >-
    Loss-of-function SCN2A variants produce autism and intellectual disability,
    sometimes with little or no epilepsy. How does reduced Nav1.2 current in
    developing excitatory neurons translate into autism and cognitive impairment
    independent of seizures, and does this reflect impaired dendritic excitability
    and synaptic maturation?
  rationale: >-
    The seizure-independent neurodevelopmental phenotype of Nav1.2 loss of
    function is mechanistically distinct from the epileptogenic arm and is only
    partially understood, yet it defines the prognosis and therapeutic targets
    for a large share of SCN2A patients.
  evidence:
  - reference: PMID:31230762
    reference_title: "The Autism-Associated Gene Scn2a Contributes to Dendritic Excitability and Synaptic Function in the Prefrontal Cortex."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "The link between an axonal sodium channel and ASD, a disorder typically attributed to synaptic or transcriptional dysfunction, is unclear."
    explanation: >-
      States the open question this knowledge gap captures: how an axonal sodium
      channel defect produces autism.
  - reference: PMID:31230762
    reference_title: "The Autism-Associated Gene Scn2a Contributes to Dendritic Excitability and Synaptic Function in the Prefrontal Cortex."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "These results reveal a novel dendritic function for NaV1.2, providing insight into cellular mechanisms probably underlying circuit and behavioral dysfunction in ASD."
    explanation: >-
      Supports the proposed dendritic-excitability/synaptic-maturation
      explanation named in the prompt, while the authors' hedged wording shows it
      remains a partial answer.
  proposed_experiments:
  - experiment_id: scn2a-lof-neurodevelopment
    name: Nav1.2 loss-of-function neurodevelopmental study
    description: >-
      Use human neurons and animal models with SCN2A loss-of-function variants
      to link reduced Nav1.2 current to dendritic excitability, synaptic
      maturation, and behavioral phenotypes independent of overt seizures.
    readouts:
    - name: Dendritic/synaptic phenotype and behavior with Nav1.2 loss
      target: "pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)"
    would_support:
    - "pathophysiology#Decreased Nav1.2 Sodium Current (Loss of Function)"
📚

References & Deep Research

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: SCN2A-Related Developmental and Epileptic Encephalopathy · 2026-07-18T18:16:01Z · View source

De-novo curation of SCN2A-related DEE (DEE11, MONDO:0013388). Granular unbundled pathophysiology modeling the gain-vs-loss-of-function dichotomy via mechanistic_hypotheses (scn2a_gain_of_function_early_onset CANONICAL; scn2a_loss_of_function_later_onset CANONICAL): SCN2A variant -> increased Nav1.2 current (GOF arm) OR decreased Nav1.2 current (LOF arm), causal edges opted into respective hypothesis_groups -> neuronal hyperexcitability/network dysfunction (conforms module) -> seizures + developmental encephalopathy (conforms). Evidence entirely from Wolff 2017 (PMID:28379373): GOF->early onset (<3mo)->sodium-channel-blocker responsive; LOF/truncating->late onset (>=3mo)->blockers rarely effective and sometimes worsen. Treatments capture the precision caveat (Na-channel blockers help GOF, worsen LOF). Three KNOWLEDGE_GAP discussions: rapid functional variant classification for treatment, direction-specific precision therapy (ASO), and the LOF autism/ID mechanism. Prevalence ~5-8/100,000 (cohort/foundation estimate, notes-only). claude_code deep research NEC-clean (SCN2A/Nav1.2/DEE11); no SCN2A GeneReviews chapter indexed in PubMed. All snippets verified exact; schema + term validation pass.

Claude Code ▸
1. Disease Information
claude-haiku-4-5-20251001, claude-opus-4-8 21 citations 2026-07-18T14:14:04.736605

1. Disease Information

Overview. SCN2A-related developmental and epileptic encephalopathy (SCN2A-DEE) is a rare, autosomal-dominant, monogenic neurodevelopmental disorder caused by pathogenic variants in SCN2A, the gene encoding the α-subunit of the brain voltage-gated sodium channel Na_V1.2. It sits within a broad SCN2A-related phenotypic spectrum that ranges from benign self-limited neonatal/infantile epilepsy through severe early- and late-onset epileptic encephalopathy to autism spectrum disorder and intellectual disability without epilepsy. The "DEE" label specifically denotes the phenotype where refractory seizures co-occur with — and contribute to — developmental impairment.

The canonical OMIM disease entity is Developmental and Epileptic Encephalopathy 11 (DEE11), "an autosomal dominant seizure disorder characterized by neonatal or infantile onset of refractory seizures with resultant delayed neurologic development and persistent neurologic abnormalities" (OMIM #613721).

Key identifiers. - Gene: SCN2A — OMIM 182390; HGNC 10588 (hgnc:10588); chromosome 2q24.3; NCBI Gene 6326; UniProt Q99250 (SCN2A_HUMAN, Na_V1.2). - Disease: OMIM #613721 (DEE11). MONDO candidate: MONDO:0012588 (developmental and epileptic encephalopathy, 11) — verify against the broader "SCN2A-related" grouping term with OAK before binding. Orphanet: the SCN2A-DEE phenotype is captured under ORPHA entries for early infantile DEE / malignant migrating partial seizures of infancy (confirm exact ORPHA code). - ICD-10: G40.4 (other generalized epilepsy and epileptic syndromes) is the usual proxy code; ICD-11: 8A61 (developmental and epileptic encephalopathies). - MeSH: covered under "Spasms, Infantile" / "Epilepsy, Generalized" / "Epileptic Syndromes"; no SCN2A-specific MeSH descriptor.

Synonyms / alternative names: SCN2A encephalopathy; SCN2A-related epilepsy; DEE11; early infantile epileptic encephalopathy 11 (EIEE11, older term); SCN2A epileptic encephalopathy; Na_V1.2 channelopathy; benign familial neonatal-infantile seizures (BFNIS, the mild end of the same spectrum, distinct phenotype).

Data provenance: Information is drawn from aggregated disease-level resources (OMIM, Orphanet, GeneReviews, HPO) and cohort literature (Wolff et al. 2017; Sanders et al. 2018), not from individual EHR records. The large phenotype cohorts (e.g., Wolff 2017, n=201) are curated case aggregations rather than population EHR extractions.

Sources: OMIM #613721, OMIM 182390, MalaCards DEE11.

2. Etiology

Primary cause — genetic. SCN2A-DEE is caused by heterozygous pathogenic variants in SCN2A, the great majority arising de novo (new mutations not inherited from either parent). There is no infectious, environmental, or acquired cause of the core disorder; it is a pure monogenic channelopathy. The severity and clinical direction are set by how the variant alters Na_V1.2 biophysics:

  • Gain-of-function (GoF) variants → increased channel activity/neuronal hyperexcitability → early-onset (<3 months) seizures / DEE.
  • Loss-of-function (LoF) variants → reduced channel activity → late-onset (>3 months) epilepsy and/or autism/intellectual disability, often without early seizures.

"SCN2A pathogenic variants cause either gain or loss of channel function, which correlates well with the clinical phenotype. Gain-of-function variants are associated with early-onset seizures... whereas loss-of-function results in late-onset severe epilepsy and/or autism." (synthesized from the genotype–phenotype literature; Wolff et al. 2017, PMID 28379373; Sanders et al. 2018, PMID 30301539).

Genetic risk factors. The causal variant itself is the risk factor — there is no known common susceptibility locus. Recurrent DEE-causing GoF hotspots include p.Arg1882Gln (R1882Q) and p.Arg853Gln (R853Q) (note R853Q is functionally a LoF/mixed variant associated with later onset and treatment resistance), p.Leu1563Val, p.Glu1211Lys, and p.Met1770Leu, among others. De novo occurrence in a gene under strong evolutionary constraint (very low tolerance to LoF in gnomAD; high pLI) is the dominant "risk mechanism."

Environmental risk factors. None established for causation. Advanced paternal age is a general risk factor for de novo mutations across the genome and is a plausible (not disorder-specific) contributor. Sex is not a strong risk modifier (see §9). No toxin, infection, or occupational exposure is implicated.

Protective factors. None genetic or environmental are established for disease occurrence. On the therapeutic-response axis, the GoF-vs-LoF distinction is the closest thing to a "modifier": GoF patients respond to sodium-channel blockers, whereas the same drugs are ineffective or harmful in LoF patients — a functional-genotype modifier of outcome rather than of onset.

Gene–environment interactions. Not a meaningful axis for this monogenic disorder; the phenotype is variant-determined. Fever and intercurrent illness can trigger seizures (as in most epilepsies) but do not modify the underlying etiology.

Sources: Wolff et al. 2017, Brain, PubMed 28379373.

3. Phenotypes

The phenotype is bimodal along the GoF/LoF axis. Below, phenotypes are grouped with suggested HPO terms, onset, severity, course, and approximate frequency. Frequencies are cohort estimates (chiefly Wolff 2017, n=201; Sanders 2018) and should carry their own evidence when a frequency: band is asserted.

Core seizure / epilepsy phenotypes:

Phenotype HPO term Onset Frequency Notes
Seizures (any) HP:0001250 Seizure Neonatal→childhood Very frequent in DEE subset Defining feature of the DEE phenotype
Neonatal onset seizures HP:0032807 Neonatal seizure / HP:0002643 Neonatal onset <28 days (GoF) Common in early-onset GoF
Infantile spasms / epileptic spasms HP:0012469 Infantile spasms ~3–12 mo Subset progress to West syndrome Hypsarrhythmia on EEG
Focal-onset seizures HP:0007359 Focal-onset seizure Variable Frequent tonic, tonic-clonic, focal, multifocal
Tonic seizures HP:0032792 Tonic seizure Early Frequent (GoF)
Migrating focal seizures of infancy HP:0032794 (migrating focal) Neonatal/infantile SCN2A a major cause of EIMFS Severe end
Status epilepticus HP:0002133 Status epilepticus Variable Occasional
Absence / myoclonic seizures HP:0002121 Absence / HP:0001336 Myoclonus >3 mo More common in later-onset "absence and myoclonic seizures were more common in patients with seizure onset after 3 months" (OMIM)
Pharmacoresistant epilepsy HP:0002133/HP:0011171 — ~50% intractable ~half achieve seizure freedom in childhood

Developmental / neurological phenotypes:

Phenotype HPO term Severity Frequency
Global developmental delay HP:0001263 Moderate–profound Very frequent
Intellectual disability HP:0001249 Mild→profound Very frequent (esp. severe DEE)
Autism spectrum disorder / autistic behavior HP:0000729 — Frequent, esp. LoF
Absent/impaired speech HP:0001344 Absent speech — Frequent in severe DEE
Axial hypotonia HP:0008936 — Frequent (infancy)
Spasticity / hypertonia HP:0001257 / HP:0001276 — Occasional (later)
Movement disorder (choreoathetosis, dystonia) HP:0100022 Abnormal movement / HP:0002072 Chorea / HP:0001332 Dystonia — Occasional; described in later-onset LoF
Microcephaly (acquired) HP:0000252 — Occasional
Cortical visual impairment HP:0100704 — Occasional in severe DEE
Feeding difficulties HP:0011968 — Frequent in severe forms
Ataxia / episodic ataxia HP:0001251 — Occasional (LoF spectrum)

Phenotype characteristics summary. - Onset: Bimodal — GoF ~neonatal to <3 months; LoF ~later infancy/childhood, sometimes with seizures only after 1–3 years or none at all (autism/ID-predominant). - Severity: Highly variable; recurrent GoF hotspots (e.g., R1882Q) trend toward the most severe DEE with profound ID. - Progression: Encephalopathy is typically static-to-progressive in early life; seizures may improve in childhood in ~50% even as developmental impairment persists — an important dissociation between seizure control and developmental trajectory. - QoL impact: Severe DEE causes profound dependence — non-verbal status, inability to walk, gastrostomy feeding, and high caregiver burden; the autism/ID-predominant LoF end causes lifelong support needs but with more preserved motor function.

Sources: OMIM #613721, Wolff et al. 2017, FamilieSCN2A clinical info.

4. Genetic / Molecular Information

Causal gene. SCN2A (Sodium Voltage-Gated Channel Alpha Subunit 2); HGNC:10588; OMIM 182390; 2q24.3. Encodes Na_V1.2, a ~2,005-aa transmembrane protein with four homologous domains (DI–DIV), each containing six segments (S1–S6); the S4 segments are voltage sensors and the DIII–DIV linker mediates fast inactivation. Na_V1.2 is expressed in the axon initial segment and unmyelinated/proximal axons of excitatory (glutamatergic) neurons, and dominates action-potential initiation and backpropagation early in development.

Pathogenic variants. - Type/class: Overwhelmingly de novo missense variants; also nonsense, frameshift, splice-site, and whole-gene deletions (the latter cluster on the LoF/autism-ID end). "SCN2A mutations are predominantly de novo missense mutations." - Classification: Per ACMG/AMP — many recurrent variants (R1882Q, R853Q, L1563V, etc.) are Pathogenic; novel missense variants are frequently VUS until functional testing resolves GoF vs LoF. Curate against ClinVar and ClinGen validity assertions (CGGV: if available). - Allele frequency: Essentially absent from population databases (gnomAD) — consistent with de novo, highly penetrant, deleterious variants. SCN2A is strongly LoF-constrained (high pLI/low LOEUF). - Somatic vs germline: Germline (de novo in the proband); rare parental germline/somatic mosaicism explains occasional recurrence in siblings (relevant to recurrence-risk counseling). - Functional consequence — the crux: - GoF: enhanced persistent current, impaired inactivation, hyperpolarizing shift of activation → neuronal hyperexcitability → early seizures. Sensitive to sodium-channel blockers. - LoF / haploinsufficiency: reduced current density, loss of function → later epilepsy and/or ASD/ID. Sodium-channel blockers ineffective or worsening. - Mixed variants: some variants show combined GoF+LoF biophysics (e.g., certain EIMFS variants), blurring the dichotomy (PMC9109789; Neurology Genetics 2025, PMC12854296).

Modifier genes. No robust modifier gene established. Genetic background likely modulates severity (as in mouse strains) but this is not clinically actionable.

Epigenetics / chromosomal abnormalities. No disorder-specific methylation signature is established. Large 2q24.3 deletions/CNVs spanning SCN2A (± neighboring SCN1A, SCN3A) produce contiguous-gene phenotypes and fall on the LoF/ASD-ID end — detectable by chromosomal microarray.

Suggested GO/gene annotations: SCN2A (hgnc:10588); GO:0005248 voltage-gated sodium channel activity; GO:0001518 voltage-gated sodium channel complex; GO:0019228 neuronal action potential; GO:0086010 membrane depolarization during action potential.

Sources: GeneCards SCN2A, Sanders et al. 2018 review PDF.

5. Environmental Information

Not a substantial contributor. SCN2A-DEE is monogenic and de novo. No toxin, radiation, pollution, occupational exposure, lifestyle factor, or infectious agent causes the disorder. As with epilepsy generally, fever, sleep deprivation, and intercurrent illness can provoke seizures in an already-established channelopathy, but these are triggers, not etiologic factors. This section is largely not applicable.

6. Mechanism / Pathophysiology

The central causal chain (GoF arm):

  1. De novo GoF missense variant in SCN2A → altered Na_V1.2 gating (impaired fast inactivation, increased persistent Na⁺ current, hyperpolarized activation).
  2. → Increased Na⁺ influx and neuronal hyperexcitability in glutamatergic cortical/hippocampal neurons (Na_V1.2 concentrated at the axon initial segment).
  3. → Excitation–inhibition imbalance and hypersynchronous network firing.
  4. → Recurrent seizures / status epilepticus beginning in the neonatal-to-early-infantile window.
  5. → Epileptic encephalopathy: ongoing epileptiform activity plus the primary channel defect impair synaptic development → developmental delay, ID, and (in severe cases) regression.

This maps cleanly onto the dismech epilepsy_excitation_inhibition_imbalance module (conserved epilepsy pathway: ion-channel/synaptic dysfunction → excitation/inhibition imbalance → neuronal hyperexcitability and hypersynchrony → seizure generation → recurrent unprovoked seizures). The GoF arm is a textbook conformer at epilepsy_excitation_inhibition_imbalance#Excitation-Inhibition Imbalance.

The LoF arm (mechanistically distinct):

  1. LoF/haploinsufficiency variant → reduced Na_V1.2 current.
  2. → In immature neurons (where Na_V1.2 dominates AP initiation) → hypoexcitability and impaired action-potential firing/backpropagation → disrupted dendritic excitability, synaptic plasticity, and circuit maturation → ASD/ID.
  3. → Paradoxically, in mature cortex, homeostatic/compensatory changes can produce network hyperexcitability and later-onset seizures — "immature glutamatergic cortical neurons from Scn2a+/− mice display decreased neuronal excitability, but mature neurons... are hyperexcitable."

This developmental-switch pathophysiology — the same gene causing hypoexcitability early and hyperexcitability late — is the mechanistic key to why one gene yields both autism-without-epilepsy and epilepsy phenotypes, and was worked out largely in mouse models (Spratt et al. 2019 Neuron; the Scn2a rodent-model review, PMC11601800).

Cell types / compartments involved: - Cell types (CL): glutamatergic/excitatory cortical pyramidal neuron (CL:0000598 pyramidal neuron; CL:0000679 glutamatergic neuron); hippocampal pyramidal neurons. Na_V1.2 is chiefly excitatory-neuron-restricted (contrast Na_V1.1/SCN1A in interneurons — hence the opposite drug logic). - Subcellular (GO CC): axon initial segment (GO:0043194); node of Ranvier / axolemma; plasma membrane voltage-gated sodium channel complex (GO:0001518). - Biological processes (GO): GO:0019228 neuronal action potential; GO:0086010 membrane depolarization during action potential; GO:0099509 regulation of presynaptic cytosolic calcium; GO:0050804 modulation of chemical synaptic transmission.

Protein dysfunction: Not misfolding/aggregation — this is a gating/biophysical defect. GoF variants shift the channel toward the open/non-inactivating state; LoF variants reduce functional channel density or trafficking. Functional consequence is resolved by patch-clamp electrophysiology and, increasingly, patient iPSC-derived neurons, which show "distinctive in vitro phenotypes" separating GoF and LoF cases (J Neurosci 2024, jneurosci.org/content/44/8/e0692232023).

Metabolic / immune involvement: None primary. No metabolic derangement, no autoimmune/inflammatory component. This is a pure electrical-signaling disorder — do not over-curate metabolic or immune mechanisms.

Tissue damage: No structural neurodegeneration is intrinsic; most brains are structurally normal on MRI (though rare cases with polymicrogyria/opercular dysplasia are reported — ScienceDirect S2950221724000242). "Damage" is functional — disrupted circuit development plus potential secondary injury from prolonged seizures/status epilepticus.

Molecular profiling / advanced tech: iPSC-derived neuron models (in vitro electrophysiology, GoF vs LoF separation); dynamic action-potential clamp; CRISPR-activation and cis-regulation functional-genomics rescue in mouse (SFARI 2025 report). Transcriptomic/proteomic disease signatures are model-derived, not clinical biomarkers.

Sources: J Neurosci iPSC study, Scn2a rodent model review PMC11601800, Sanders 2018.

7. Anatomical Structures Affected

  • Organ / system: Central nervous system, primarily cerebral cortex and hippocampus (UBERON:0000955 brain; UBERON:0000956 cerebral cortex; UBERON:0002421 hippocampal formation). Body system: nervous system (UBERON:0001016). No primary involvement of other organ systems.
  • Tissue/cell level: Gray-matter neuronal tissue; specifically excitatory glutamatergic pyramidal neurons (CL:0000598) of neocortex and hippocampus. GABAergic interneurons are relatively spared (mechanistically important — the inverse of SCN1A/Dravet).
  • Subcellular: Axon initial segment (GO:0043194) and proximal axon — where Na_V1.2 sets AP threshold; also nodes of Ranvier and somatodendritic membrane for backpropagation.
  • Localization / lateralization: Bilateral, diffuse cortical involvement; seizures may be focal/multifocal or generalized. Structural MRI is usually normal (bilateral, non-lesional). Rare malformation-of-cortical-development cases are the exception.

Sources: Sanders 2018, ScienceDirect polymicrogyria case.

8. Temporal Development

  • Onset: Bimodal and variant-determined. GoF/DEE → neonatal to <3 months (often first days of life). LoF → >3 months to years, and the autism/ID-predominant subset may never develop epilepsy. Onset pattern is typically acute for seizures against a chronic/insidious developmental backdrop.
  • Stages / course:
  • Early-onset GoF DEE: neonatal seizures → possible evolution to West syndrome / infantile spasms (3–12 mo) → childhood epilepsy with variable control. Encephalopathy tracks alongside.
  • Later-onset: childhood epilepsy, sometimes with movement disorder and episodic ataxia in the LoF spectrum.
  • Progression rate: Variable. About half of patients achieve seizure freedom during childhood; the other half remain intractable (OMIM). Crucially, seizure improvement does not guarantee developmental improvement — cognitive impairment often persists.
  • Course pattern: Chronic, lifelong. Seizures can be relapsing or evolve through age-dependent syndromes; developmental impairment is generally static-to-slowly-progressive rather than neurodegenerative.
  • Critical periods: The early-infantile window is both the period of maximal seizure burden and the developmental window where intervention could most plausibly alter trajectory — the rationale for early functional testing to guide drug choice, and for the emerging ASO trials targeting infants.

Sources: OMIM #613721, Wolff et al. 2017.

9. Inheritance and Population

Epidemiology. - SCN2A-related disorders have an estimated prevalence around 8 per 100,000, with disease-causing variants arising in roughly 7.5 per 100,000 births (FamilieSCN2A / cohort estimates). Over 1,000 individuals have been identified worldwide, and numbers are rising with expanded genetic testing. For a structured Prevalence record: measure_type: BIRTH_PREVALENCE or POINT_PREVALENCE, prevalence_class: BAND_1_5_PER_10000, rate_per_100000: 7.5–8.0, with the source phrasing in notes. SCN2A is among the most frequently implicated single genes in DEE and in de novo ASD. - Incidence is not precisely established; de novo occurrence and ascertainment through sequencing complicate rate estimates.

Inheritance (genetic). - Pattern: Autosomal dominant (HP:0000006); the overwhelming majority are de novo (relationship_type causal; onset from a new heterozygous variant). - Penetrance: Effectively complete/high for pathogenic de novo DEE variants; the mild familial BFNIS end shows near-complete penetrance too but for a benign phenotype. - Expressivity: Highly variable — even the same recurrent variant can produce a range of severity. - Anticipation: Not applicable (not a repeat-expansion disorder). - Germline mosaicism: Documented (parental gonadal/somatic mosaicism) — recurrence risk to siblings is low but not zero (~1–2% empiric), which matters for counseling. - Founder effects / consanguinity: Not relevant — de novo dominant, no ancestry-specific founder alleles, no consanguinity role. - Carrier frequency: Not applicable (dominant, de novo).

Population demographics. - Affected populations: No ethnic/geographic predilection — occurs worldwide across all ancestries (expected for de novo dominant). - Sex ratio: Roughly equal (≈1:1); SCN2A is autosomal, so no strong sex bias, though ASD ascertainment can skew reported series slightly male. - Age distribution: Onset in neonatal period through early childhood; the population is predominantly pediatric, with a growing cohort of surviving adolescents/adults.

Sources: FamilieSCN2A clinical info, Decoding SCN2A Variants (J Clin Med 2025, PMC12156426).

10. Diagnostics

Genetic testing — the diagnostic anchor. - First-line: Next-generation sequencing — epilepsy/DEE gene panels, whole-exome sequencing (WES), or whole-genome sequencing (WGS) identify the causal SCN2A variant. Given the DEE presentation, early genetic testing is now standard of care because the result directly changes treatment (GoF → sodium-channel blockers; LoF → avoid them). MAXO: MAXO:0000922-family genetic testing / molecular diagnostic actions. - Chromosomal microarray (CMA): detects 2q24.3 deletions/CNVs involving SCN2A (LoF/ASD-ID end). - Single-gene SCN2A testing: appropriate when the phenotype strongly suggests it (e.g., neonatal-onset SCB-responsive seizures). - Variant interpretation: ACMG/AMP classification via ClinVar/ClinGen; functional characterization (patch-clamp, iPSC-neuron electrophysiology) is increasingly used to resolve GoF vs LoF for VUS and to guide therapy — arguably the most consequential "diagnostic" beyond variant detection.

Clinical / supportive tests: - EEG: seizure characterization; may show multifocal epileptiform discharges, hypsarrhythmia (if West syndrome), or migrating focal ictal patterns. Emerging work explores EEG features as correlates of variant function and outcome (medRxiv 2023.10.24.23296360). - Brain MRI: usually normal; excludes structural/malformative mimics (rare polymicrogyria/opercular dysplasia cases exist). - Metabolic workup / lumbar puncture: typically normal — used mainly to exclude treatable metabolic epilepsies (e.g., pyridoxine-dependent, GLUT1) in the differential before or alongside genetic testing.

Differential diagnosis: other DEE genes — SCN1A (Dravet; note opposite drug logic), SCN8A, KCNQ2, KCNT1 (EIMFS), STXBP1, CDKL5, PRRT2; treatable metabolic epilepsies (pyridoxine-dependent/ALDH7A1, PNPO deficiency, GLUT1). The distinguishing feature is the SCN2A variant plus its functional direction and the SCB-response pattern.

Screening: No population newborn screening. Cascade testing of parents (for recurrence risk and mosaicism) and reproductive counseling (prenatal/PGT for a known familial variant, chiefly relevant to mosaic parents) apply.

Sources: Efficacy of sodium channel blockers, PMID 27876397, EEG insights medRxiv.

11. Outcome / Prognosis

  • Survival / mortality: No single reliable survival figure; life expectancy is reduced in severe DEE, with risk of SUDEP (sudden unexpected death in epilepsy), status epilepticus, and complications of profound disability (aspiration, respiratory infection). Milder LoF/ASD-ID phenotypes have near-normal life expectancy.
  • Morbidity / disability: Severe DEE → profound intellectual disability, non-verbal status, motor impairment, need for gastrostomy and full-time care. This is the dominant burden.
  • Disease course: ~50% achieve seizure freedom in childhood; the remainder have intractable epilepsy. Developmental/cognitive impairment frequently persists despite seizure control.
  • Prognostic factors:
  • Age of onset — earlier onset (neonatal GoF, especially recurrent severe variants like R1882Q) predicts worse developmental outcome.
  • Functional variant class — GoF-early tends to be SCB-responsive (better seizure control) but can still carry severe encephalopathy; LoF/late is SCB-resistant.
  • Specific variant identity — recurrent hotspots have characteristic severity signatures.
  • Prognostic biomarkers: No validated molecular biomarker; variant function (GoF/LoF from electrophysiology or in-silico prediction) is the best available prognostic/therapeutic stratifier; EEG features under investigation.

Sources: Wolff et al. 2017, OMIM #613721.

12. Treatment

Treatment is genotype/function-directed — the single most important precision-medicine lesson in the whole disorder. It's the closest thing in epilepsy to reading the thermostat before you touch the dial.

Pharmacotherapy — the GoF/LoF split:

  • GoF (early-onset, <3 months): Sodium-channel blockers (SCBs) are first-line and often effective. Agents: phenytoin, carbamazepine, oxcarbazepine, lacosamide, lamotrigine, zonisamide. Documented dramatic responses to IV phenytoin loading in refractory neonatal cases.

    "Patients with the early seizure onset respond better to antiepileptic drugs that non-selectively block sodium channel function, such as phenytoin." (Wong et al. 2016, PMID 27876397 — verify exact quote on fetch)

MAXO/agents: treatment_term NCIT:C15986 Pharmacotherapy; therapeutic_agent CHEBI — phenytoin (CHEBI:8107), carbamazepine (CHEBI:3387), lamotrigine (CHEBI:6367), oxcarbazepine (CHEBI:7822), lacosamide (CHEBI:31771 — verify), zonisamide (CHEBI:10127 — verify). therapeutic_modality: SMALL_MOLECULE.

  • LoF (late-onset >3 months, and ASD/ID): SCBs are ineffective or can worsen seizures — avoid as monotherapy. Use broad-spectrum agents: levetiracetam, valproate, benzodiazepines, topiramate; and consider ketogenic diet (MAXO:0000088 dietary intervention / NCIT ketogenic diet term). Response is generally poorer than in the GoF group.

Precision / disease-modifying therapies (the frontier):

  • Antisense oligonucleotides (ASOs) — GoF-directed. Elsunersen (PRAX-222), an intrathecally-administered ASO designed to selectively lower SCN2A expression in GoF patients, is the flagship program (Praxis Precision Medicines). In the EMBRAVE Phase 1/2 study, early data showed a 44% median seizure reduction after three monthly intrathecal doses; topline results were slated for the first half of 2026. Regulatory status: FDA Breakthrough Therapy Designation (June 2026), Orphan Drug, Rare Pediatric Disease designations, plus EMA Orphan/PRIME. Registrational trial NCT07019922 (recruiting); earlier NCT05737784. therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE; aso_mechanism: RNASE_H_KNOCKDOWN; target_gene: SCN2A (hgnc:10588). This maps to the dismech antisense_oligonucleotide_therapy#Pathogenic mRNA Accumulation conformance target (RNase-H knockdown paradigm). A published case reports ASO treatment in a preterm infant with early-onset SCN2A-DEE (PMC12283366 / PMC12854296-adjacent — verify).

  • Upregulation strategies — LoF-directed (preclinical). Because LoF needs more Na_V1.2, ASO knockdown is exactly wrong; instead, CRISPR-activation (CRISPRa) and cis-regulation gene therapy to increase endogenous Scn2a expression have rescued neural excitability and behavioral phenotypes in Scn2a⁺/⁻ mice (SFARI 2025; ScienceDirect S266732582300033X). Still preclinical.

Supportive / rehabilitative: developmental therapies — physical therapy (MAXO:0000011), occupational therapy, speech therapy, feeding/nutrition support (gastrostomy where needed, MAXO supportive care MAXO:0000950), and management of comorbid autism/behavior. Genetic counseling (MAXO:0000079) for the family.

Pharmacogenomics: The operative "pharmacogenomic" axis here is the SCN2A variant's own functional class dictating SCB response — not classic CYP-based metabolism (though standard phenytoin/carbamazepine PGx — e.g., HLA-B*15:02 for carbamazepine SJS risk — still applies to those drugs).

Treatment strategy: Confirm variant → determine GoF vs LoF (functional data or informed prediction) → GoF: SCB first-line; LoF: avoid SCBs, use broad-spectrum ± ketogenic diet → escalate to precision ASO (GoF) as trials mature.

Sources: Praxis FDA Breakthrough release, NCT07019922, NCT05737784, Wong et al. PMID 27876397, SFARI cis-regulation rescue.

13. Prevention

  • Primary prevention: None possible for a de novo dominant disorder — you can't prevent a new mutation. No vaccine, no modifiable risk factor.
  • Secondary prevention / early detection: Rapid genetic diagnosis in a neonate/infant with unexplained seizures is the actionable lever — it enables function-directed treatment early, potentially reducing seizure burden and (hoped, unproven) improving developmental trajectory. This is prevention of complications, not of disease occurrence.
  • Tertiary prevention: Optimizing seizure control (correct drug class), SUDEP-risk mitigation, managing feeding/respiratory complications, and developmental support to maximize function.
  • Genetic counseling & reproductive options: For families with an affected child, counseling covers the low-but-nonzero sibling recurrence risk from parental mosaicism; prenatal diagnosis / preimplantation genetic testing are options when a familial (mosaic) variant is known. MAXO:0000079 genetic counseling.
  • Public health / behavioral / immunization: Not applicable.

Sources: FamilieSCN2A clinical info.

14. Other Species / Natural Disease

  • Taxonomy / orthologs: SCN2A is conserved across mammals. Mouse ortholog Scn2a (NCBI Gene 110876; MGI); rat Scn2a; conserved across vertebrates. NCBITaxon:10090 (Mus musculus), NCBITaxon:10116 (Rattus norvegicus).
  • Natural disease in other species: No well-characterized naturally-occurring SCN2A channelopathy is established in companion animals or wildlife analogous to the human disorder — the animal knowledge base here is dominated by engineered models, not natural disease (check OMIA for any spontaneous variants). This section is largely not applicable beyond experimental models.
  • Comparative biology: The developmental expression switch (Na_V1.2 dominant in immature excitatory neurons, partly ceded to Na_V1.6/SCN8A with maturation) is conserved rodent↔human, which is why mouse models are informative. Evolutionary conservation of the four-domain sodium-channel architecture is deep (across the SCN gene family).
  • Zoonosis / transmission: Not applicable — genetic disorder, not transmissible.

Sources: Scn2a rodent model review, PMC11601800.

15. Model Organisms

Mouse is the workhorse and the models split neatly along the human GoF/LoF axis:

  • LoF / haploinsufficiency model — Scn2a⁺/⁻ (heterozygous knockout): Viable and fertile. Recapitulates the autism/ID + late-seizure end: reduced excitability of immature neurons but hyperexcitable mature neurons; impaired hippocampal excitability, excitatory synaptic drive, LTP, and spatial learning/memory (PMC6582764); anxiety, sociability, memory-flexibility, and hyperactivity phenotypes, with ampakine CX516 rescuing hyperactivity (PMC6437867). Spratt et al. (Neuron 2019) established the dendritic-excitability mechanism. Applications: modeling the ASD/ID arm and testing expression-restoring therapies (CRISPRa, cis-regulation, AAV-Scn2a gene therapy — SFARI 2025).
  • GoF models: knock-in of specific human GoF variants recapitulate early-onset seizures/hyperexcitability and are the substrate for testing expression-lowering ASOs (gapmer ASOs reduce seizures in GoF-modeling mice — the preclinical basis for elsunersen; bioRxiv 2020.09.09.289900).
  • Conditional / cell-type-specific models: Cre-based conditional knockouts dissect excitatory-neuron-specific contributions and developmental timing.
  • In vitro / cellular: Patient iPSC-derived neurons distinguish GoF vs LoF functionally in a human background (J Neurosci 2024); heterologous expression (HEK/Xenopus) for patch-clamp biophysics; dynamic action-potential clamp for functional prediction.

Phenotype recapitulation & limitations: Mouse models reproduce the core electrophysiology and many behaviors, and their GoF/LoF dichotomy mirrors humans well — a genuine strength. Limitations: rodents don't capture human-specific cortical development, the full cognitive/language phenotype, or the precise developmental timing of the Na_V1.2→Na_V1.6 handoff; strain background modifies severity; and behavioral autism analogs are imperfect proxies. For dismech curation, tag mouse/iPSC evidence as MODEL_ORGANISM / IN_VITRO respectively — keep it distinct from human-clinical support for human phenotypes.

Resources: MGI (mouse Scn2a), IMPC/KOMP (knockout alleles), Cellosaurus (iPSC lines), and the FamilieSCN2A-supported model repositories.

Sources: Scn2a rodent model review PMC11601800, Scn2a+/− behavior/CX516, PMC6437867, Hippocampal Scn2a haploinsufficiency, PMC6582764, gene-therapy review.

Curation-ready summary (dismech hooks)

  • Module conformance: Primary → epilepsy_excitation_inhibition_imbalance (GoF arm; #Excitation-Inhibition Imbalance). Treatment → antisense_oligonucleotide_therapy (#Pathogenic mRNA Accumulation, RNase-H knockdown, elsunersen). Consider a cardiac_ion_channel_repolarization-style channelopathy framing conceptually, but epilepsy module is the correct fit.
  • Key genes/terms: SCN2A (hgnc:10588), Na_V1.2 (UniProt Q99250); GO:0005248, GO:0043194, GO:0019228; CL:0000598 pyramidal neuron; UBERON:0000956 cerebral cortex.
  • Anchor PMIDs (verify snippets before YAML): 28379373 (Wolff 2017 Brain — genotype/phenotype + therapeutic implications); 30301539 (Sanders 2018 Trends Neurosci — GoF/LoF framework); 27876397 (Wong 2016 — SCB efficacy in early-onset); Spratt 2019 Neuron (haploinsufficiency mechanism — confirm PMID); iPSC J Neurosci 2024 (44(8):e0692232023).
  • Genotype-directed therapy is the headline — curate the GoF→SCB-responsive vs LoF→SCB-resistant split explicitly, with separate evidence for each direction, and the ASO (GoF-lowering) vs upregulation (LoF-raising) therapeutic mirror-image.

The one-line mental model to carry into curation: same gene, two opposite failures of one sodium channel — jammed-open (GoF) burns early with seizures and answers to sodium-channel blockers; jammed-shut (LoF) starves developing circuits into autism/ID and shrugs those same drugs off — and the whole treatment strategy, down to whether you add or subtract the gene's own message, hinges on which way it broke.

One caveat worth repeating for the record: several 2026-dated regulatory items (elsunersen Breakthrough designation, EMBRAVE topline) come straight from company press releases and trial registries — solid for the treatment-pipeline narrative, but they're not peer-reviewed literature, so cite them as evidence_source: OTHER (or the trial's clinicaltrials: reference) rather than dressing them up as clinical-trial primary evidence.